董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yuichi Iwaki | 男 | Director,President and Chief Executive Officer | 67 | 193.63万美元 | 未持股 | 2017-04-27 |
| Jeff Himawan | 男 | Chairman | 52 | 未披露 | 未持股 | 2017-04-27 |
| Yutaka Kobayashi | 男 | Director | 53 | 8.62万美元 | 未持股 | 2017-04-27 |
| Yoshio Ishizaka | 男 | Director | 77 | 9.62万美元 | 未持股 | 2017-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ryan Selhorn | 男 | Chief Financial Officer | 35 | 5.88万美元 | 未持股 | 2017-04-27 |
| Yuichi Iwaki | 男 | Director,President and Chief Executive Officer | 67 | 193.63万美元 | 未持股 | 2017-04-27 |
| Masatsune Okajima | 男 | Vice President and Head of Japanese Office | 49 | 81.59万美元 | 未持股 | 2017-04-27 |
| Kazuko Matsuda | 女 | Chief Medical Officer | 51 | 117.53万美元 | 未持股 | 2017-04-27 |
| Geoffrey O'Brien | 男 | Vice President | 48 | 73.96万美元 | 未持股 | 2017-04-27 |
董事简历
中英对照 | 中文 | 英文- Yuichi Iwaki
-
Yuichi Iwaki，医学博士和哲学博士，2000年9月到2007年3月，他是我们建立初期的董事会主席。2005年7月他是我们的执行主席。2005年9月他是首席执行官。2006年3月他是我们的总裁和首席执行官。2013年11月到2014年4月，他是首席财务官。2001年9月到2007年1月，他是我们融资交易和业务发展活动的顾问。1994年到2008年，他是Avigen公司的董事会成员。他拥有南加州大学（the University of Southern California）医学院的泌尿外科，外科手术和病理三个教授职位。1992年开始他是移植免疫学和免疫遗传学实验室主任。他也是日本大学（Nihon University）医学院和九州大学（Kyushu University）的客座教授。在加入南加州大学（the University of Southern California）医学院前，1989年到1991年，他拥有匹兹堡大学（the University of Pittsburgh）医学院的手术和病理学部门的教授职位。他从日本札幌的札幌医科大学（Sapporo Medical School）获得医学博士和哲学博士的学位。他是超过200同行评审和超过40本书的章节的出版物的作者。他通过超过25年的研究和投资策略来建议制药公司和风险资本基金。他在一些生物技术公司董事会任职。在他医学背景，与日本领先的生物技术公司的关系和作为教授以及制药公司的顾问的丰富经验，董事会相信他有适当的技巧成为我们的董事会一员。
Yuichi Iwaki M.D., Ph.D. is a founder of the company's Company and served as the Chairman of the Board of Directors from our inception in September 2000 to March 2007 becoming Executive Chairman in July 2005 Acting Chief Executive Officer as of September 2005 and President and Chief Executive Officer as of March 2006. From September 2001 until January 2007 Dr. Iwaki also served as our consultant in connection with financing transactions and business development activities. Dr. Iwaki was a member of the board of directors of Avigen, Inc. from 1994 to 2008. He holds three professorships at the University of Southern California School of Medicine in the Departments of Urology, Surgery and Pathology and has been Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. Dr. Iwaki is also a visiting professor at the Toho University School of Medicine. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held two professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan. Dr. Iwaki is the author of more than 200 peer-reviewed publications and more than 40 book chapters. - Yuichi Iwaki，医学博士和哲学博士，2000年9月到2007年3月，他是我们建立初期的董事会主席。2005年7月他是我们的执行主席。2005年9月他是首席执行官。2006年3月他是我们的总裁和首席执行官。2013年11月到2014年4月，他是首席财务官。2001年9月到2007年1月，他是我们融资交易和业务发展活动的顾问。1994年到2008年，他是Avigen公司的董事会成员。他拥有南加州大学（the University of Southern California）医学院的泌尿外科，外科手术和病理三个教授职位。1992年开始他是移植免疫学和免疫遗传学实验室主任。他也是日本大学（Nihon University）医学院和九州大学（Kyushu University）的客座教授。在加入南加州大学（the University of Southern California）医学院前，1989年到1991年，他拥有匹兹堡大学（the University of Pittsburgh）医学院的手术和病理学部门的教授职位。他从日本札幌的札幌医科大学（Sapporo Medical School）获得医学博士和哲学博士的学位。他是超过200同行评审和超过40本书的章节的出版物的作者。他通过超过25年的研究和投资策略来建议制药公司和风险资本基金。他在一些生物技术公司董事会任职。在他医学背景，与日本领先的生物技术公司的关系和作为教授以及制药公司的顾问的丰富经验，董事会相信他有适当的技巧成为我们的董事会一员。
- Yuichi Iwaki M.D., Ph.D. is a founder of the company's Company and served as the Chairman of the Board of Directors from our inception in September 2000 to March 2007 becoming Executive Chairman in July 2005 Acting Chief Executive Officer as of September 2005 and President and Chief Executive Officer as of March 2006. From September 2001 until January 2007 Dr. Iwaki also served as our consultant in connection with financing transactions and business development activities. Dr. Iwaki was a member of the board of directors of Avigen, Inc. from 1994 to 2008. He holds three professorships at the University of Southern California School of Medicine in the Departments of Urology, Surgery and Pathology and has been Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. Dr. Iwaki is also a visiting professor at the Toho University School of Medicine. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held two professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan. Dr. Iwaki is the author of more than 200 peer-reviewed publications and more than 40 book chapters.
- Jeff Himawan
-
Jeff Himawan，自2010年3月公司成立起在董事会任职，自2007年7月起在Horizon Pharma USA的董事会任职。1999年，他加入一家风投公司 Essex Woodlands Health Ventures, L.P.，在此他如今担任董事总经理。目前，他也在Catalyst生命科学有限公司、MediciNova有限公司、Light Sciences Oncology有限公司和Symphogen有限公司的董事会任职。先前，他从2001年起在 Iomai Corporation的董事会任职，直到2007年该公司被 Intercell AG收购。他联合创立了一家风投公司Seed-One Ventures，在此他从1996年至2001年担任董事总经理。他持有麻省理工大学生物学学士学位，哈佛大学生物化学和分离药理学博士学位。
Jeff Himawan,has been a managing director of Essex Woodlands Health Ventures, a venture capital firm, since 2004. Prior to that, he was an adjunct partner at Essex Woodlands from 1999 to 2001, and he was a venture partner from 2001 to 2004. Dr. Himawan co-founded Seed-One Ventures, an early-stage venture capital firm, where he served as a managing director from 1996 to 2001. Dr. Himawan serves on the board of directors of MediciNova, Inc., a public biopharma company(1), NexEos Bio, Inc., a private biotechnology company, and Light Sciences Oncology, Inc., a private biotechnology company. Previously, Dr. Himawan served on the board of directors of Catalyst Biosciences, Inc., a public biopharma company, from 2010 to 2020. He received a bachelor of science degree in biology from the Massachusetts Institute of Technology and a doctorate in biological chemistry and molecular pharmacology from Harvard University. - Jeff Himawan，自2010年3月公司成立起在董事会任职，自2007年7月起在Horizon Pharma USA的董事会任职。1999年，他加入一家风投公司 Essex Woodlands Health Ventures, L.P.，在此他如今担任董事总经理。目前，他也在Catalyst生命科学有限公司、MediciNova有限公司、Light Sciences Oncology有限公司和Symphogen有限公司的董事会任职。先前，他从2001年起在 Iomai Corporation的董事会任职，直到2007年该公司被 Intercell AG收购。他联合创立了一家风投公司Seed-One Ventures，在此他从1996年至2001年担任董事总经理。他持有麻省理工大学生物学学士学位，哈佛大学生物化学和分离药理学博士学位。
- Jeff Himawan,has been a managing director of Essex Woodlands Health Ventures, a venture capital firm, since 2004. Prior to that, he was an adjunct partner at Essex Woodlands from 1999 to 2001, and he was a venture partner from 2001 to 2004. Dr. Himawan co-founded Seed-One Ventures, an early-stage venture capital firm, where he served as a managing director from 1996 to 2001. Dr. Himawan serves on the board of directors of MediciNova, Inc., a public biopharma company(1), NexEos Bio, Inc., a private biotechnology company, and Light Sciences Oncology, Inc., a private biotechnology company. Previously, Dr. Himawan served on the board of directors of Catalyst Biosciences, Inc., a public biopharma company, from 2010 to 2020. He received a bachelor of science degree in biology from the Massachusetts Institute of Technology and a doctorate in biological chemistry and molecular pharmacology from Harvard University.
- Yutaka Kobayashi
-
Yutaka Kobayashi，2013年10月开始就是董事。他有超过20年的商业经验。他是许多公司的顾问或特别顾问。2001年他是日本上议院（Upper House）的成员，2007年再次入选。2005年他是日本贸易与工业的经济部副部长。他从早稻田大学（Waseda University）毕业，是在约翰霍普金斯大学（Johns Hopkins University）尼采高级国际研究学院研究员。
Yutaka Kobayashi has served as a director since October 2013. He has more than 20 years of experience in business. He has served as a consultant or special advisor to various companies. In addition, he was elected a member of Upper House in Japan in 2001 and re-elected in 2007. He also served as Vice Minister of Economy, Trade and Industry in Japan in 2005. He graduated from Waseda University and was a Fellow at Nitze School of Advanced International Studies at Johns Hopkins University. - Yutaka Kobayashi，2013年10月开始就是董事。他有超过20年的商业经验。他是许多公司的顾问或特别顾问。2001年他是日本上议院（Upper House）的成员，2007年再次入选。2005年他是日本贸易与工业的经济部副部长。他从早稻田大学（Waseda University）毕业，是在约翰霍普金斯大学（Johns Hopkins University）尼采高级国际研究学院研究员。
- Yutaka Kobayashi has served as a director since October 2013. He has more than 20 years of experience in business. He has served as a consultant or special advisor to various companies. In addition, he was elected a member of Upper House in Japan in 2001 and re-elected in 2007. He also served as Vice Minister of Economy, Trade and Industry in Japan in 2005. He graduated from Waseda University and was a Fellow at Nitze School of Advanced International Studies at Johns Hopkins University.
- Yoshio Ishizaka
-
Yoshio Ishizaka，2014年4月开始，他就是董事。他在丰田汽车公司（Toyota Motor Corporation TMC）的市场和产品发展部工作超过50年。他丰富的经验包括日本，欧洲和美国的作业。在日本一桥大学（Hitotsubashi University）毕业并获得法律学位后，他开始了在丰田汽车公司的事业。1986年到1990年，他在美国丰田汽车销售公司（Toyota Motor Sales, U.S.A, Inc.）担任高级副总裁和首席协调官，他对雷克萨斯分部的工作起帮助作用。1990年，他接受丰田汽车公司（TMC）的欧洲分部董事总经理的任命，在欧洲，他建立了一个综合性的，局部组织。1992年，他被任命到丰田汽车公司（TMC）的董事会，1996年到1999年，回到了美国丰田汽车公司（TMS U.S.A.）当总裁。1999年他回到了日本，他被提升为海外业务主管的高级董事总经理。2011年，他被提升为丰田汽车公司（TMC）海外营运部的执行副总裁，2005年他成为了海外丰田汽车公司（TMC Board）的高级顾问。
Yoshio Ishizaka has served as a director since April 2014. He has 50 years of experience in marketing and product development with Toyota Motor Corporation TMC. His international experience includes assignments in Japan, Europe and the U.S. Mr. Ishizaka started his career at TMC after graduating with a degree in law from the Hitotsubashi University in Japan. He served as Senior Vice President and Chief Coordinating Officer at Toyota Motor Sales, U.S.A, Inc. (TMS) from 1986 to 1990 and was instrumental in the development of the Lexus Division. He accepted the appointment of General Manager of TMC’s Europe Division in 1990 where he built an integrated, local organization in Europe. In 1992 he was named to TMC’s Board of Directors and returned to TMS U.S.A. to serve as President from 1996 to 1999. He returned to Japan in 1999 whereupon he was promoted to Senior Managing Director in charge of overseas operations. In 2001 he was promoted to Executive VP in overseas operations for TMC, and in 2005 became Senior Advisor to the TMC Board. - Yoshio Ishizaka，2014年4月开始，他就是董事。他在丰田汽车公司（Toyota Motor Corporation TMC）的市场和产品发展部工作超过50年。他丰富的经验包括日本，欧洲和美国的作业。在日本一桥大学（Hitotsubashi University）毕业并获得法律学位后，他开始了在丰田汽车公司的事业。1986年到1990年，他在美国丰田汽车销售公司（Toyota Motor Sales, U.S.A, Inc.）担任高级副总裁和首席协调官，他对雷克萨斯分部的工作起帮助作用。1990年，他接受丰田汽车公司（TMC）的欧洲分部董事总经理的任命，在欧洲，他建立了一个综合性的，局部组织。1992年，他被任命到丰田汽车公司（TMC）的董事会，1996年到1999年，回到了美国丰田汽车公司（TMS U.S.A.）当总裁。1999年他回到了日本，他被提升为海外业务主管的高级董事总经理。2011年，他被提升为丰田汽车公司（TMC）海外营运部的执行副总裁，2005年他成为了海外丰田汽车公司（TMC Board）的高级顾问。
- Yoshio Ishizaka has served as a director since April 2014. He has 50 years of experience in marketing and product development with Toyota Motor Corporation TMC. His international experience includes assignments in Japan, Europe and the U.S. Mr. Ishizaka started his career at TMC after graduating with a degree in law from the Hitotsubashi University in Japan. He served as Senior Vice President and Chief Coordinating Officer at Toyota Motor Sales, U.S.A, Inc. (TMS) from 1986 to 1990 and was instrumental in the development of the Lexus Division. He accepted the appointment of General Manager of TMC’s Europe Division in 1990 where he built an integrated, local organization in Europe. In 1992 he was named to TMC’s Board of Directors and returned to TMS U.S.A. to serve as President from 1996 to 1999. He returned to Japan in 1999 whereupon he was promoted to Senior Managing Director in charge of overseas operations. In 2001 he was promoted to Executive VP in overseas operations for TMC, and in 2005 became Senior Advisor to the TMC Board.
高管简历
中英对照 | 中文 | 英文- Ryan Selhorn
Ryan Selhorn，他于2012年3月16日被任命为临时首席财务官。他于2013年7月加入Signature Analytics San Diego LLC（会计服务公司），担任运营副总裁，此前曾任职Grant Thornton LLP10年，最近担任高级审计实践经理，随后任职国家并购集团。他曾任职多个行业的上市和私人公司，包括生命科学、生物技术和医疗设备。他是一个有执照的注册会计师，并持有Georgetown University的会计和金融学士学位。
Ryan Selhorn has served as our Vice President and Chief Financial Officer since April 27 2018. From July 2013 to April 2018 he was the Chief Financial Officer and Chief Accounting Officer of Signature Analytics, an outsourced finance and accounting firm. From October 2003 to July 2013 he was an Audit Senior Manager with Grant Thornton LLP, a financial accounting firm. Mr. Selhorn has significant experience with venture financings, public equity offerings, public debt offerings, mergers and acquisitions, interaction with the SEC and PCAOB, and implementation and monitoring compliance with the requirements of the Sarbanes-Oxley Act. Additionally, Mr. Selhorn has participated in several financial due diligence processes for acquisitions and capital financings. Mr. Selhorn received his B.S. in Accounting and Finance from Georgetown University, McDonough School of Business, and he is a certified public accountant in California.- Ryan Selhorn，他于2012年3月16日被任命为临时首席财务官。他于2013年7月加入Signature Analytics San Diego LLC（会计服务公司），担任运营副总裁，此前曾任职Grant Thornton LLP10年，最近担任高级审计实践经理，随后任职国家并购集团。他曾任职多个行业的上市和私人公司，包括生命科学、生物技术和医疗设备。他是一个有执照的注册会计师，并持有Georgetown University的会计和金融学士学位。
- Ryan Selhorn has served as our Vice President and Chief Financial Officer since April 27 2018. From July 2013 to April 2018 he was the Chief Financial Officer and Chief Accounting Officer of Signature Analytics, an outsourced finance and accounting firm. From October 2003 to July 2013 he was an Audit Senior Manager with Grant Thornton LLP, a financial accounting firm. Mr. Selhorn has significant experience with venture financings, public equity offerings, public debt offerings, mergers and acquisitions, interaction with the SEC and PCAOB, and implementation and monitoring compliance with the requirements of the Sarbanes-Oxley Act. Additionally, Mr. Selhorn has participated in several financial due diligence processes for acquisitions and capital financings. Mr. Selhorn received his B.S. in Accounting and Finance from Georgetown University, McDonough School of Business, and he is a certified public accountant in California.
- Yuichi Iwaki
Yuichi Iwaki，医学博士和哲学博士，2000年9月到2007年3月，他是我们建立初期的董事会主席。2005年7月他是我们的执行主席。2005年9月他是首席执行官。2006年3月他是我们的总裁和首席执行官。2013年11月到2014年4月，他是首席财务官。2001年9月到2007年1月，他是我们融资交易和业务发展活动的顾问。1994年到2008年，他是Avigen公司的董事会成员。他拥有南加州大学（the University of Southern California）医学院的泌尿外科，外科手术和病理三个教授职位。1992年开始他是移植免疫学和免疫遗传学实验室主任。他也是日本大学（Nihon University）医学院和九州大学（Kyushu University）的客座教授。在加入南加州大学（the University of Southern California）医学院前，1989年到1991年，他拥有匹兹堡大学（the University of Pittsburgh）医学院的手术和病理学部门的教授职位。他从日本札幌的札幌医科大学（Sapporo Medical School）获得医学博士和哲学博士的学位。他是超过200同行评审和超过40本书的章节的出版物的作者。他通过超过25年的研究和投资策略来建议制药公司和风险资本基金。他在一些生物技术公司董事会任职。在他医学背景，与日本领先的生物技术公司的关系和作为教授以及制药公司的顾问的丰富经验，董事会相信他有适当的技巧成为我们的董事会一员。
Yuichi Iwaki M.D., Ph.D. is a founder of the company's Company and served as the Chairman of the Board of Directors from our inception in September 2000 to March 2007 becoming Executive Chairman in July 2005 Acting Chief Executive Officer as of September 2005 and President and Chief Executive Officer as of March 2006. From September 2001 until January 2007 Dr. Iwaki also served as our consultant in connection with financing transactions and business development activities. Dr. Iwaki was a member of the board of directors of Avigen, Inc. from 1994 to 2008. He holds three professorships at the University of Southern California School of Medicine in the Departments of Urology, Surgery and Pathology and has been Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. Dr. Iwaki is also a visiting professor at the Toho University School of Medicine. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held two professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan. Dr. Iwaki is the author of more than 200 peer-reviewed publications and more than 40 book chapters.- Yuichi Iwaki，医学博士和哲学博士，2000年9月到2007年3月，他是我们建立初期的董事会主席。2005年7月他是我们的执行主席。2005年9月他是首席执行官。2006年3月他是我们的总裁和首席执行官。2013年11月到2014年4月，他是首席财务官。2001年9月到2007年1月，他是我们融资交易和业务发展活动的顾问。1994年到2008年，他是Avigen公司的董事会成员。他拥有南加州大学（the University of Southern California）医学院的泌尿外科，外科手术和病理三个教授职位。1992年开始他是移植免疫学和免疫遗传学实验室主任。他也是日本大学（Nihon University）医学院和九州大学（Kyushu University）的客座教授。在加入南加州大学（the University of Southern California）医学院前，1989年到1991年，他拥有匹兹堡大学（the University of Pittsburgh）医学院的手术和病理学部门的教授职位。他从日本札幌的札幌医科大学（Sapporo Medical School）获得医学博士和哲学博士的学位。他是超过200同行评审和超过40本书的章节的出版物的作者。他通过超过25年的研究和投资策略来建议制药公司和风险资本基金。他在一些生物技术公司董事会任职。在他医学背景，与日本领先的生物技术公司的关系和作为教授以及制药公司的顾问的丰富经验，董事会相信他有适当的技巧成为我们的董事会一员。
- Yuichi Iwaki M.D., Ph.D. is a founder of the company's Company and served as the Chairman of the Board of Directors from our inception in September 2000 to March 2007 becoming Executive Chairman in July 2005 Acting Chief Executive Officer as of September 2005 and President and Chief Executive Officer as of March 2006. From September 2001 until January 2007 Dr. Iwaki also served as our consultant in connection with financing transactions and business development activities. Dr. Iwaki was a member of the board of directors of Avigen, Inc. from 1994 to 2008. He holds three professorships at the University of Southern California School of Medicine in the Departments of Urology, Surgery and Pathology and has been Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992. Dr. Iwaki is also a visiting professor at the Toho University School of Medicine. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held two professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan. Dr. Iwaki is the author of more than 200 peer-reviewed publications and more than 40 book chapters.
- Masatsune Okajima
Masatsune Okajima，2006年9月开始他是日本办事处的副总裁和领导。在加入我们前，2002年开始他是大和证券公司（Daiwa Securities SMBC Co., Ltd.）的临时总经理。1999年到2002年，他是大和证券资本市场有限公司（Daiwa Securities SB Capital Markets Co., Ltd. ）现在的大和证券公司（Daiwa Securities SMBC Co., Ltd.）的经理。1996年到1999年，他是住友资本证券股份有限公司（Sumitomo Capital Securities Co., Ltd. ）的经理。1991年到1996年，他在住友银行公司（ Sumitomo Bank, Ltd. 现在的三井住友银行Mitsui Sumitomo Bank）担任不同职位。他获得了东京理科大学（Tokyo Science University）科学和技术部学士学位。
Masatsune Okajima was appointed as our Vice President and Head of Japanese Office in September 2006. Prior to joining us, he served as Deputy General Manager at Daiwa Securities SMBC Co., Ltd. beginning in 2002. From 1999 through 2002 Mr. Okajima served as Manager, Daiwa Securities SB Capital Markets Co., Ltd. now Daiwa Securities SMBC Co., Ltd.. From 1996 to 1999 Mr. Okajima served as Manager, Sumitomo Capital Securities Co., Ltd. and between 1991 and 1996 Mr. Okajima served in various positions at Sumitomo Bank, Ltd. (now Mitsui Sumitomo Bank). Mr. Okajima received a B.S. degree from the Department of Science and Technology, Tokyo Science University.- Masatsune Okajima，2006年9月开始他是日本办事处的副总裁和领导。在加入我们前，2002年开始他是大和证券公司（Daiwa Securities SMBC Co., Ltd.）的临时总经理。1999年到2002年，他是大和证券资本市场有限公司（Daiwa Securities SB Capital Markets Co., Ltd. ）现在的大和证券公司（Daiwa Securities SMBC Co., Ltd.）的经理。1996年到1999年，他是住友资本证券股份有限公司（Sumitomo Capital Securities Co., Ltd. ）的经理。1991年到1996年，他在住友银行公司（ Sumitomo Bank, Ltd. 现在的三井住友银行Mitsui Sumitomo Bank）担任不同职位。他获得了东京理科大学（Tokyo Science University）科学和技术部学士学位。
- Masatsune Okajima was appointed as our Vice President and Head of Japanese Office in September 2006. Prior to joining us, he served as Deputy General Manager at Daiwa Securities SMBC Co., Ltd. beginning in 2002. From 1999 through 2002 Mr. Okajima served as Manager, Daiwa Securities SB Capital Markets Co., Ltd. now Daiwa Securities SMBC Co., Ltd.. From 1996 to 1999 Mr. Okajima served as Manager, Sumitomo Capital Securities Co., Ltd. and between 1991 and 1996 Mr. Okajima served in various positions at Sumitomo Bank, Ltd. (now Mitsui Sumitomo Bank). Mr. Okajima received a B.S. degree from the Department of Science and Technology, Tokyo Science University.
- Kazuko Matsuda
Kazuko Matsuda于2011年9月1日被任命为首席医疗官。Matsuda博士于2010年4月至2011年9月担任临床开发副总裁。2008年8月至2009年11月，Matsuda博士担任南加州大学凯克医学院助理教授。2005年8月至2008年7月，Matsuda博士担任洛杉矶儿童医院临床研究员。Matsuda博士开始在密歇根州立大学内科/儿科住院，并在Loma Linda大学完成儿科住院。Matsuda医生是美国和日本的董事会认证儿科医生。Matsuda博士拥有札幌医科大学医学院的医学博士和哈佛大学公共卫生学院的公共卫生硕士学位。
Kazuko Matsuda was appointed as Chief Medical Officer on September 1 2011. Dr. Matsuda served as Vice President of Clinical Development from April 2010 to September 2011.From August 2008 to November 2009 Dr. Matsuda served as an assistant professor with the University of Southern California, Keck School of Medicine. From August 2005 to July 2008 Dr. Matsuda served as Clinical Fellow with the Children's Hospital Los Angeles. Dr. Matsuda commenced her residency in internal medicine/pediatrics at Michigan State University and completed a pediatric residency at Loma Linda University. Dr. Matsuda is a board certified pediatrician in both the United States and Japan. Dr. Matsuda holds an M.D. and Ph.D. from Sapporo Medical University School of Medicine and an MPH from Harvard University, School of Public Health.- Kazuko Matsuda于2011年9月1日被任命为首席医疗官。Matsuda博士于2010年4月至2011年9月担任临床开发副总裁。2008年8月至2009年11月，Matsuda博士担任南加州大学凯克医学院助理教授。2005年8月至2008年7月，Matsuda博士担任洛杉矶儿童医院临床研究员。Matsuda博士开始在密歇根州立大学内科/儿科住院，并在Loma Linda大学完成儿科住院。Matsuda医生是美国和日本的董事会认证儿科医生。Matsuda博士拥有札幌医科大学医学院的医学博士和哈佛大学公共卫生学院的公共卫生硕士学位。
- Kazuko Matsuda was appointed as Chief Medical Officer on September 1 2011. Dr. Matsuda served as Vice President of Clinical Development from April 2010 to September 2011.From August 2008 to November 2009 Dr. Matsuda served as an assistant professor with the University of Southern California, Keck School of Medicine. From August 2005 to July 2008 Dr. Matsuda served as Clinical Fellow with the Children's Hospital Los Angeles. Dr. Matsuda commenced her residency in internal medicine/pediatrics at Michigan State University and completed a pediatric residency at Loma Linda University. Dr. Matsuda is a board certified pediatrician in both the United States and Japan. Dr. Matsuda holds an M.D. and Ph.D. from Sapporo Medical University School of Medicine and an MPH from Harvard University, School of Public Health.
- Geoffrey O'Brien
Geoffrey O'Brien, J.D./M.B.A.于 2013 年 10 月晋升为副总裁，此前自 2012 年起担任 Medicinova, Inc. 业务发展和战略规划高级总监，并自 2009 年起担任业务发展总监。在加入 Medicinova, Inc. 之前。 , O'Brien 先生曾在 UBS Securities、Nomura Securities 和 Punk Ziegel 等多家投资银行担任制药和生物技术公司的股票研究分析师，并于 2004 年至 2008 年担任副总裁。他还是唐纳森的医疗保健投资银行家 , Lufkin & Jenrette/Credit Suisse First Boston。 在读研究生之前，他在 The Liposome Company 成功开发了一种生物技术产品。 O'Brien 先生获得了学士学位。 以优异成绩获得特拉华大学化学博士学位，并同时在范德比尔特法学院和范德比尔特大学欧文管理研究生院完成了法学博士和工商管理硕士学位。
Geoffrey O'Brien, J.D./M.B.A.was promoted to Vice President in October 2013 having previously served as Medicinova, Inc. Senior Director, Business Development and Strategic Planning since 2012 and as Director, Business Development since 2009. Prior to joining Medicinova, Inc., Mr. O'Brien was an equity research analyst covering pharmaceutical and biotechnology companies at several investment banks including UBS Securities, Nomura Securities, and Punk Ziegel, and was a Vice President from 2004 to 2008. He was also a healthcare investment banker at Donaldson, Lufkin & Jenrette/Credit Suisse First Boston. Prior to graduate school, he worked on the successful development of a biotechnology product at The Liposome Company. Mr. O'Brien received a B.S. in chemistry, cum laude, from the University of Delaware and completed his J.D. and M.B.A. simultaneously at Vanderbilt Law School and Owen Graduate School of Management at Vanderbilt University.- Geoffrey O'Brien, J.D./M.B.A.于 2013 年 10 月晋升为副总裁，此前自 2012 年起担任 Medicinova, Inc. 业务发展和战略规划高级总监，并自 2009 年起担任业务发展总监。在加入 Medicinova, Inc. 之前。 , O'Brien 先生曾在 UBS Securities、Nomura Securities 和 Punk Ziegel 等多家投资银行担任制药和生物技术公司的股票研究分析师，并于 2004 年至 2008 年担任副总裁。他还是唐纳森的医疗保健投资银行家 , Lufkin & Jenrette/Credit Suisse First Boston。 在读研究生之前，他在 The Liposome Company 成功开发了一种生物技术产品。 O'Brien 先生获得了学士学位。 以优异成绩获得特拉华大学化学博士学位，并同时在范德比尔特法学院和范德比尔特大学欧文管理研究生院完成了法学博士和工商管理硕士学位。
- Geoffrey O'Brien, J.D./M.B.A.was promoted to Vice President in October 2013 having previously served as Medicinova, Inc. Senior Director, Business Development and Strategic Planning since 2012 and as Director, Business Development since 2009. Prior to joining Medicinova, Inc., Mr. O'Brien was an equity research analyst covering pharmaceutical and biotechnology companies at several investment banks including UBS Securities, Nomura Securities, and Punk Ziegel, and was a Vice President from 2004 to 2008. He was also a healthcare investment banker at Donaldson, Lufkin & Jenrette/Credit Suisse First Boston. Prior to graduate school, he worked on the successful development of a biotechnology product at The Liposome Company. Mr. O'Brien received a B.S. in chemistry, cum laude, from the University of Delaware and completed his J.D. and M.B.A. simultaneously at Vanderbilt Law School and Owen Graduate School of Management at Vanderbilt University.